Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m

Smith & Nephew (LSE:SN, NYSE:SNN) priced a cash tender offer for up to $250M of its 2.032% Senior Notes due 2030. The offer expires today, with a settlement date expected on September 18, 2026. The tender offer consideration is $878.90 per $1,000 principal amount. The company may prorate the offer if oversubscribed.

UK inflation rose to 2.9% year-on-year in July, driven by energy prices. Analysts expect further inflation due to energy and food price pressures. The FTSE 100 opened higher, led by mining stocks like Rio Tinto, Glencore, and Anglo American. Rio Tinto is reportedly in talks for a $600M investment in McEwen Copper. Shell and BP also gained, while Smith & Nephew dropped over 3% after its CFO stepped down. Geopolitical tensions in the Middle East are pushing oil prices higher. Oxford Nanopore Techn

Romania’s Nuclearelectrica (BVB: SNN) reported net profit of RON 1.18 billion for H1 2026, up 36.6% year on year, per its Bucharest Stock Exchange filing. Operating profit rose 33.7% on higher electricity sales revenues and removal of the Energy Transition Fund contribution, partly offset by higher operating costs. The Aug. 13 shutdown due to low Danube levels may reduce revenues.

SMITH & NEPHEW PLC (SNN) furnished an SEC Form 6-K — earnings release. This report on Form 6-K shall be deemed incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-277815) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently fi

Romania’s Cernavodă nuclear plant began steps to shut Unit 2 on Aug 13 due to very low Danube flow affecting cooling water. Nuclearelectrica (BVB: SNN) previously shut Unit 1 in late July for the same drought. The outage may last about two weeks, with Rovinari 4 restarted and energy curbs and imports expected. Nuclearelectrica also flagged force majeure notices for supply contracts.

Smith & Nephew (SNN) reported Q2 2026 underlying revenue growth of 1.6%, with softness in U.S. Orthopaedics and Advanced Wound Bioactives. First-half trading profit was $566 million, helped by $128 million efficiency savings. It revised 2026 revenue outlook to about 4% and guided full-year free cash flow around $800 million.